ENRIGHT PATRICK G 4

What Happened

• Patrick G. Enright, a director of Vera Therapeutics, received a derivative equity award on May 21, 2026 covering 17,084 shares. The Form 4 reports the acquisition at $0.00 (transaction code A — grant/award), so no cash was paid at grant and no immediate shares were delivered.

Key Details

• Transaction date: 2026-05-21; Filing date (Form 4): 2026-05-26 (filed after the transaction date).
• Transaction type/code: Grant/Award (A) of a derivative instrument covering 17,084 shares; reported price $0.00.
• Shares owned after the transaction: not specified in the information provided.
• Footnote (vesting): The award will vest in full on the earlier of (a) the first anniversary of the grant date or (b) the Company's 2027 annual meeting, provided continuous service. The award also vests in full upon a change in control, subject to continued service (see F1).
• Timeliness: The Form 4 was filed five days after the transaction date, which is later than the typical 2-business-day reporting requirement; late filings reduce the promptness of public disclosure.

Context

• This is an equity award (derivative/option-like grant) with future vesting, not an immediate purchase or sale of shares — it does not indicate an immediate change in open-market holdings or a cash transaction.
• Vesting and a change-in-control acceleration provision mean the award becomes valuable only if Enright remains in service or if a qualifying corporate event occurs.